POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval

By sjmartinez • May 28, 2023

Bikhchandani M, Amersi F, Hendifar A, Gangi A, Osipov A, Zaghiyan K, Atkins K, Cho M, Aguirre F, Hazelett D, Alvarez R, Zhou L, Hitchins M, Gong J. POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval. Genes (Basel). 2023 May 8;14(5):1054. doi: 10.3390/genes14051054. PMID: 37239414; PMCID: PMC10218075.

Tags: Cedars Sinai DoM, Checkpoint Inhibitor, Colon cancer, Hematology/Oncology, high tumor mutation burden, immunotherapy, MSS, POLE, Publications

Oxidative stress-regulatory role of miR-10b-5p in the diabetic human cornea revealed through integrated multi-omics analysis

Zha D, Gamez J, Ebrahimi SM, Wang Y, Verma N, Poe AJ, White S, Shah R, Kramerov AA, Sawant OB, Santiskulvong C, Stotland AB, Wang[...]

Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung cancer

Chan AA, Sankar K, Reckamp KL, Díaz B, Lee DJ. Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung[...]

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan[...]